These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9036120)

  • 1. [Immunologic aspects of infections with papillomaviruses. Prospects for a vaccine].
    Höpfl R; Heim K
    Hautarzt; 1996 Oct; 47(10):739-43. PubMed ID: 9036120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Papillomavirus-like particles for serology and vaccine development.
    Kirnbauer R
    Intervirology; 1996; 39(1-2):54-61. PubMed ID: 8957670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice.
    Revaz V; Benyacoub J; Kast WM; Schiller JT; De Grandi P; Nardelli-Haefliger D
    Virology; 2001 Jan; 279(1):354-60. PubMed ID: 11145916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Biology of the papillomavirus infections: V. Vaccine developments].
    Seilles E; Riethmuller D; Mougin C
    Ann Biol Clin (Paris); 1999; 57(5):517-24. PubMed ID: 10518053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine.
    Jochmus I; Schäfer K; Faath S; Müller M; Gissmann L
    Arch Med Res; 1999; 30(4):269-74. PubMed ID: 10573627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunology of the human papilloma virus in relation to cancer.
    Wu TC
    Curr Opin Immunol; 1994 Oct; 6(5):746-54. PubMed ID: 7826530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Possibilities of vaccination against HPV infections in cervix carcinoma].
    Gissmann L
    Zentralbl Gynakol; 2001 May; 123(5):299-301. PubMed ID: 11449623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Perspectives for the development of vaccines and immunotherapy against cervico-uterine cancer].
    Guzmán-Rojas L; Alcocer-González JM; Madrid-Marina V
    Salud Publica Mex; 1998; 40(1):38-46. PubMed ID: 9567657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospects for a vaccine against human papillomavirus.
    Hines JF; Ghim S; Schlegel R; Jenson AB
    Obstet Gynecol; 1995 Nov; 86(5):860-6. PubMed ID: 7566866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.
    Roden RB; Yutzy WH; Fallon R; Inglis S; Lowy DR; Schiller JT
    Virology; 2000 May; 270(2):254-7. PubMed ID: 10792983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16.
    Kowalczyk DW; Wlazlo AP; Shane S; Ertl HC
    Vaccine; 2001 May; 19(25-26):3583-90. PubMed ID: 11348726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HPV vaccines: preclinical development.
    Gissmann L
    Arch Med Res; 2009 Aug; 40(6):466-70. PubMed ID: 19853186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immunology of animal papillomaviruses.
    Nicholls PK; Stanley MA
    Vet Immunol Immunopathol; 2000 Feb; 73(2):101-27. PubMed ID: 10690928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospects for human papillomavirus vaccine development: emerging HPV vaccines.
    Hines JF; Ghim SJ; Jenson AB
    Curr Opin Obstet Gynecol; 1998 Feb; 10(1):15-9. PubMed ID: 9484624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against papillomavirus with a polynucleotide vaccine.
    Donnelly JJ; Martinez D; Jansen KU; Ellis RW; Montgomery DL; Liu MA
    J Infect Dis; 1996 Feb; 173(2):314-20. PubMed ID: 8568291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses.
    Rocha-Zavaleta L; Alejandre JE; Garcia-Carranca A
    J Med Virol; 2002 Jan; 66(1):86-95. PubMed ID: 11748663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic vaccination for the treatment of mucosotropic human papillomavirus-associated disease.
    Chu NR
    Expert Opin Biol Ther; 2003 Jun; 3(3):477-86. PubMed ID: 12783616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of neutralizing antibodies to papillomaviruses by anti-idiotypic antibodies.
    Christensen ND; Reed CA; Cladel NM
    Virology; 1995 Jul; 210(2):292-301. PubMed ID: 7542415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune response to human papillomaviruses and the prospects for human papillomavirus-specific immunisation.
    Tindle RW; Frazer IH
    Curr Top Microbiol Immunol; 1994; 186():217-53. PubMed ID: 8205843
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.